

20. Talley NJ, Meineche-Schmidt V, Paré P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). *Aliment Pharmacol Ther.* 1998;12(11):1055-65.
21. Black CJ, Paine PA, Agrawal A, et al. British Society of Gastroenterology guidelines on the management of functional dyspepsia. *Gut.* 2022;71(9):1697-723.
22. Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. *Gastroenterology.* 2022;162(4):1334-42.
23. Kroupa R, Katinova I, Pavlik T, et al. Incidence trends of esophageal cancer in the Czech Republic by histological subtype and stage and prescription rate of acid suppressing drugs. *Cancer Epidemiol.* 2020;69:101853.
24. Park J-H, Lee J, Yu S-Y, et al. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease. *BMC Geriatr.* 2020;20(1):407.
25. Thurber KM, Otto AO, Stricker SL. Proton pump inhibitors: Understanding the associated risks and benefits of long-term use. *Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm.* 2023;80(8):487-94.
26. Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. *BMC Nephrol.* 2013;14(1):150.
27. Antoniou T, Macdonald EM, Hollands S, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. *Can Med Assoc Open Access J.* 2015;3(2):E166-71.
28. Arora P, Gupta A, Golzy M, et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. *BMC Nephrol* 2016;17(1):112.
29. Lazarus B, Chen Y, Wilson FP, et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. *JAMA Intern Med.* 2016;176(2):238-46.
30. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. *Gastroenterology.* 2019;157(3):682-691.e2.

ON-LINE KURZ

Správná volba antibiotik



PŘEDNÁŠKY

- ▶ **Která antibiotika preferujeme při antibiotické preskripci?**
MUDr. Milan Trojánek, Ph.D.
- ▶ **Jak poznat, že pacient s respirační infekcí potřebuje antibiotika**
MUDr. Lukáš Kohout
- ▶ **Která konkrétní antibiotika volit u jednotlivých syndromů**
MUDr. Marek Štefan, MBA
- ▶ **Aktualizace doporučení pro antibiotickou léčbu akutního bakteriálního zánětu středouší v dětském věku – MUDr. Pavel Horník et al.**

ODBOBNÝ GARANT

MUDr. Milan Trojánek, Ph.D.

POŘADATEL

Společnost SOLEN, s. r. o., ve spolupráci s Klinikou infekčních nemocí a cestovní medicíny 2. LF UK a FN Motol, Praha

POČET KREDITŮ **2**Registrace **ZDARMA**

TERMÍN

prosinec 2023
až listopad 2024
dostupný na
online.solen.cz

PARTNER

M.C.F.
KLOSTERFRAU
HEALTHCARE GROUP

MEDIÁLNÍ PARTNEŘI

Medicína
pro praxiPedie
pro praxi